IncobotulinumtoxinA in clinical literature.

Z. Paul Lorenc, Jeffrey M. Kenkel, Steven Fagien, Haideh Hirmand, Mark S. Nestor, Anthony P. Sclafani, Jonathan M Sykes, Heidi A. Waldorf

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


IncobotulinumtoxinA is the third neurotoxin type A to be approved for aesthetic use in the United States. Because incobotulinumtoxinA has been in use in Europe for some time, the clinical literature is fairly replete with references to its properties and characteristics, as well as its safety and efficacy. In North America, 2 pivotal trials, referred to as GL-1 and GL-2, investigated the safety and efficacy of incobotulinumtoxinA in the glabellar region; both are currently in press with another journal. Other published studies of incobotulinumtoxinA are also described in depth in this article, including reports on aesthetic indications, diffusion, therapeutic indications, and studies pertaining to the preclinical and clinical pharmacology of incobotulinumtoxinA. Topics addressed include potency variability, mean concentration, stability and dissociation, and endopeptide immunoassay.

Original languageEnglish (US)
JournalAesthetic surgery journal / the American Society for Aesthetic Plastic surgery
Issue number1 Suppl
StatePublished - Mar 2013
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'IncobotulinumtoxinA in clinical literature.'. Together they form a unique fingerprint.

Cite this